AbbVie, Inc.

AbbVie, Inc.

AbbVie, Inc.

Overview
Date Founded

2013

Headquarters

1 North Waukegan Road North Chicago IL 60064-6400

Type of Company

Public

Employees (Worldwide)

30K

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Contact Data
Trying to get in touch with decision makers at AbbVie, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Vice Chairman & President

Chief Financial Officer & Executive Vice President

Vice Chairman, External Affairs & Chief Legal Officer

Vice Chairman, Chief Commercial Officer

Executive Vice President & Chief Human Resources Officer

Chief Strategy Officer

Vice President, Principal Accounting Officer & Controller

Executive Vice President, Operations

Senior Vice President, US Commercial Operations

Board of Directors

Chief Executive Officer at AbbVie, Inc.

President at United Airlines Holdings, Inc.

Former Chief Executive Officer at Northern Trust Corporation

Former Partner at Clayton Dubilier & Rice LLC

President at Abbott Laboratories (Puerto Rico), Inc.

President & Chief Executive Officer at Austin Investment Advisors

Former Chief Financial Officer at Caterpillar, Inc.

SEE Schedule at Northwestern Memorial Healthcare Group Return

Dean at Yale University - Yale School of Medicine

Former Director & Senior Vice President at The Boston Consulting Group, Inc.

Paths to AbbVie, Inc.
Potential Connections via
Relationship Science
You
AbbVie, Inc.
Owners & Shareholders
Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Details Hidden

Price Associates' investment approach is based on the belief that fundamental proprietary research drives value-added, active investment management. The firm maintains a global research platform that includes interconnected teams of research analysts. Their strategy begins with bottom-up analysis. Price Associates uses both qualitative and quantitative analysis to evaluate investment opportunities. Portfolios are created with a commitment to diversification and a strict attention to valuation appropriate to the chosen investment universe. The firm focuses its analytical process on three areas of research: the industry, the contracts issued, and the creditworthiness of each individual issuer. Price Associates' Private Asset management Group provides balanced, equity and fixed-income investment management services to meet the needs of individuals, trusts, endowments, foundations, institutions, retirement plans and IRAs and other entities.

Details Hidden

JPMIM utilizes different methods of analysis that are tailored for each of the investment strategies they offer their clients. They use different methods of analysis and investment strategies in formulating investment advice or managing assets. The firm employs global fundamental research, quantitative valuation tools and bottom-up portfolio construction methods. Research analysts evaluate the US market by sector, while globally-based portfolio managers and analysts cover the international capital markets. JPMIM integrates the skills of their research analysts with those of experienced portfolio managers and economists to leverage information and choose the most fundamentally attractive investments.

Recent Transactions
Details Hidden

AbbVie, Inc. purchases Allergan Plc

Details Hidden

AbbVie, Inc. purchases Mavupharma, Inc. from Frazier Healthcare Partners, Alpine Bioventures GP LLC

Details Hidden

AbbVie, Inc. purchases Stemcentrx, Inc. from Sequoia Capital, Western Technology Investment, The Founders Fund Management LLC, Artis Ventures Management LP

Insider Transactions
Details Hidden
Transaction Advisors
Legal Advisor

Advised onAbbVie, Inc. purchases Allergan Plc

Investment Advisor

Advised onAbbVie, Inc. purchases Allergan Plc

Legal Advisor

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Associate

Advised onAbbVie, Inc. purchases Mavupharma, Inc. from Frazier Healthcare Partners, Alpine Bioventures GP LLC

Legal Advisor

Advised onAbbVie, Inc. purchases Allergan Plc

Lender

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Advisors & Consultants
Legal Advisor

Partner at Jones Day

Legal Advisor

Co-Chair, Product Liability Litigation Practice Group at Shook, Hardy & Bacon LLP

Legal Advisor

Partner at Latham & Watkins LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

SpartanNash Co. engages in the distribution of grocery products to military commissaries in the U.S. It operates through the following segments: Military, Food Distribution and Retail. The Military segment sells and distributes grocery products primarily to U.S. military commissaries and exchanges. The Food Distribution segment distributes groceries to independent and corporate owned grocery retailers using multi-platform sales approach. The Retail segment operates retail supermarkets in the Midwest, which operate under banners of Family Fare Supermarkets, No Frills, Bag 'N Save, Family Fresh Markets, D&W Fresh Markets, Sun Mart and Econo Foods. The company was founded in 1917 and is headquartered in Grand Rapids, MI.

Key Stats and Financials As of 2019
Market Capitalization
$169B
Total Enterprise Value
$159B
Earnings Per Share
$5.28
Revenue
$33.3B
Net Profit
$7.84B
EBITDA
$15.9B
EBITDAMargin
47.89%
Total Debt
$67.1B
Total Equity
$-8.17B
Enterprise Value Sales
4.77x
Enterprise Value EBITDAOperating
9.93x
TEVNet Income
20.22x
Debt TEV
0.42x
Three Year Compounded Annual Growth Rate Of Revenue
9.07%
Non-Profit Donations & Grants
$1,000 - $4,999
2019
$100 +
2019
$20K - $50K
2019
Political Donations
$750
2014
$1,000
2014
$750
2014
Investments
Details Hidden

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Details Hidden

Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA.

Details Hidden

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Investors
Details Hidden

Chief Executive Officer at Innocrin Pharmaceuticals, Inc.

Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Managing Partner at Vivo Capital LLC

Suppliers
Galapagos NV Biotechnology | Mechelen, Belgium

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Neurocrine Biosciences Inc. Hospitals & Patient Services | San Diego, CA

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Seattle Genetics, Inc. Pharmaceuticals | Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Awards & Honors
Rank #123
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #123
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AbbVie, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AbbVie, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AbbVie, Inc..